ArticleMolecular therapy : the journal of the American Society of Gene Therapy2014
Characterisation of a novel Fc conjugate of macrophage colony-stimulating factor.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 106 citations in OpenAlex.
- CSF1R regulates monocyte subset differentiation and intracellular metabolism.Nature communications · 2026Article
- Depletion and replacement of tissue-resident macrophages in mice with germ-line deletion of a conserved enhancer in the Csf1r locus.Development (Cambridge, England) · 2026Article
- Administration of human macrophage colony-stimulating factor-mFc fusion protein increases macrophage phagocytic capacity and stimulates liver regeneration in mice.Journal of inflammation (London, England) · 2026Article
- Dissecting the development of bovine testicular tissue using spatial transcriptomics.Journal of animal science and biotechnology · 2026Article
- Article
- Perisurgical colony stimulating factor one treatment ameliorates liver ischaemia/reperfusion injury in rats.World journal of gastroenterology · 2025Article
- Wild-type bone marrow cells repopulate tissue resident macrophages and reverse the impacts of homozygous CSF1R mutation.PLoS genetics · 2025Article
- Macrophages as Multifaceted Orchestrators of Tissue Repair: Bridging Inflammation, Regeneration, and Therapeutic Innovation.Journal of inflammation research · 2025Review
- Single-cell RNA sequencing reveals peripheral blood leukocyte responses to spinal cord injury in mice with humanised immune systems.Journal of neuroinflammation · 2024Article
- Platelet-derived circulating soluble P-selectin is sufficient to induce hematopoietic stem cell mobilization.Stem cell research & therapy · 2023Article
- Testicular macrophages are recruited during a narrow fetal time window and promote organ-specific developmental functions.Nature communications · 2023Article
- CSF1R as a Therapeutic Target in Bone Diseases: Obvious but Not so Simple.Current osteoporosis reports · 2022Review
- Article
- Cell origin and niche availability dictate the capacity of peritoneal macrophages to colonize the cavity and omentum.Immunology · 2022Article
- Hypoxia shapes the immune landscape in lung injury and promotes the persistence of inflammation.Nature immunology · 2022Article
- A kinase-dead Csf1r mutation associated with adult-onset leukoencephalopathy has a dominant inhibitory impact on CSF1R signalling.Development (Cambridge, England) · 2022Article
- Therapeutic potential of macrophage colony-stimulating factor in chronic liver disease.Disease models & mechanisms · 2022Article
- CSF1R-dependent macrophages control postnatal somatic growth and organ maturation.PLoS genetics · 2021Article
- Dermal bacterial LPS-stimulation reduces susceptibility to intradermal Trypanosoma brucei infection.Scientific reports · 2021Article
- Stable colony-stimulating factor 1 fusion protein treatment increases hematopoietic stem cell pool and enhances their mobilisation in mice.Journal of hematology & oncology · 2021Article
Corrections and comments
- Commented on by
Authors and funding
21 authors at 4 institutions in 2 countries.
Funding
Abstract
We have produced an Fc conjugate of colony-stimulating factor (CSF) 1 with an improved circulating half-life. CSF1-Fc retained its macrophage growth-promoting activity, and did not induce proinflammatory cytokines in vitro. Treatment with CSF1-Fc did not produce adverse effects in mice or pigs. The impact of CSF1-Fc was examined using the Csf1r-enhanced green fluorescent protein (EGFP) reporter gene in MacGreen mice. Administration of CSF1-Fc to mice drove extensive infiltration of all tissues by Csf1r-EGFP positive macrophages. The main consequence was hepatosplenomegaly, associated with proliferation of hepatocytes. Expression profiles of the liver indicated that infiltrating macrophages produced candidate mediators of hepatocyte proliferation including urokinase, tumor necrosis factor, and interleukin 6. CSF1-Fc also promoted osteoclastogenesis and produced pleiotropic effects on other organ systems, notably the testis, where CSF1-dependent macrophages have been implicated in homeostasis. However, it did not affect other putative CSF1 targets, notably intestine, where Paneth cell numbers and villus architecture were unchanged. CSF1 has therapeutic potential in regenerative medicine in multiple organs. We suggest that the CSF1-Fc conjugate retains this potential, and may permit daily delivery by injection rather than continuous infusion required for the core molecule.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.